Key Points
- Jollibee plans to spin off and list its international business in the US by late 2027 to sharpen valuation and strategy.
- Overseas operations now account for nearly half of revenue, highlighting the shift toward global growth.
- Execution risks remain high, but a US listing could unlock capital access and brand visibility critical for long-term competition.
Jollibee Foods Corp., the Philippine fast-food powerhouse long viewed as a regional champion, is taking a decisive step toward global capital markets by planning to spin off its international operations and pursue a US stock market listing by late 2027. The announcement immediately resonated with investors, sending Jollibee shares sharply higher and underscoring growing confidence in the group’s overseas growth story at a time when global quick-service restaurant competition is intensifying.
The move reflects a broader strategic recalibration as Jollibee increasingly positions itself against entrenched global players such as McDonald’s and Yum! Brands. By separating its international business from its domestic Philippine operations, management aims to give investors clearer visibility into two very different growth and risk profiles within the same corporate group.
A Dual-Listing Strategy to Unlock Valuation
Under the proposed structure, Jollibee’s overseas assets will be housed under a new entity, Jollibee Foods Corporation International, which will seek a US listing while the Philippine business remains listed locally. Existing shareholders are expected to receive shares in the international unit equivalent to their holdings at the time of listing, effectively allowing them to participate directly in the global expansion narrative.
Market reaction suggests investors see the move as value-accretive. Analysts argue that the separation allows the mature, cash-generative Philippine business to be valued independently from the faster-growing but more volatile international arm. While this may reduce the relative weighting of the domestic unit in certain equity indices, it also removes a long-standing valuation discount tied to blending disparate business models under one ticker.
International Expansion Comes Into Focus
Jollibee’s international footprint has grown rapidly over the past two decades. The group operates more than 10,300 stores globally, with nearly two-thirds located outside the Philippines across over 30 countries, including the US, China, Canada, and Vietnam. Overseas operations contributed roughly 43% of consolidated revenue in the first nine months of the year, highlighting how central global markets have become to the company’s future.
The company’s expansion strategy has relied heavily on acquisitions, with more than $1.1 billion deployed in cross-border deals since 2000. These include US-based brands such as Smashburger and Coffee Bean & Tea Leaf, as well as more recent additions like South Korea’s Compose Coffee. While some acquisitions have struggled operationally, management continues to view portfolio diversification as critical to building scale and brand relevance beyond its home market.
Competitive Pressures and Execution Risk
Despite the enthusiasm, execution risks remain significant. The US fast-food market is saturated, highly competitive, and cost-sensitive, with rising labor and input expenses pressuring margins across the sector. Turning overseas brands into consistent profit contributors has proven challenging, and investors will likely scrutinize profitability and same-store sales trends more closely as the international unit prepares for a potential US debut.
At the same time, a US listing could materially broaden Jollibee’s investor base, improve access to capital, and elevate its global brand profile. In an environment where scale, technology, and marketing spend increasingly determine competitive advantage, those benefits could prove decisive.
Looking ahead, the success of Jollibee’s planned spinoff will hinge on its ability to demonstrate that its international operations can deliver sustainable growth and margin improvement. If executed well, the transaction could mark a turning point, not just for Jollibee, but for how emerging-market consumer brands tap global capital to challenge established Western incumbents.
Comparison, examination, and analysis between investment houses
Leave your details, and an expert from our team will get back to you as soon as possible
* This article, in whole or in part, does not contain any promise of investment returns, nor does it constitute professional advice to make investments in any particular field.
To read more about the full disclaimer, click here- sagi habasov
- •
- 7 Min Read
- •
- ago 3 days
SKN | Is General Motors Hitting the Brakes on EVs After a $6 Billion Charge?
General Motors is taking another sharp accounting hit tied to its electric vehicle ambitions, underscoring the growing gap between early
- ago 3 days
- •
- 7 Min Read
General Motors is taking another sharp accounting hit tied to its electric vehicle ambitions, underscoring the growing gap between early
- Lior mor
- •
- 6 Min Read
- •
- ago 3 days
SKN | Merck Eyes Revolution Medicines in Strategic Cancer Drug Expansion
Merck is reportedly in discussions to acquire Revolution Medicines, a clinical-stage biotechnology company focused on targeted cancer therapies, according
- ago 3 days
- •
- 6 Min Read
Merck is reportedly in discussions to acquire Revolution Medicines, a clinical-stage biotechnology company focused on targeted cancer therapies, according
- sagi habasov
- •
- 7 Min Read
- •
- ago 4 days
SKN | Can Eli Lilly Sustain Growth Beyond GLP-1s With Its $1.2 Billion Ventyx Acquisition?
Eli Lilly’s agreement to acquire Ventyx Biosciences for $1.2 billion in cash signals a deliberate strategic pivot as the pharmaceutical
- ago 4 days
- •
- 7 Min Read
Eli Lilly’s agreement to acquire Ventyx Biosciences for $1.2 billion in cash signals a deliberate strategic pivot as the pharmaceutical
- Ronny Mor
- •
- 6 Min Read
- •
- ago 5 days
SKN | Lilly’s Talks With Ventyx Signal Renewed Deal Appetite in Biopharma
Eli Lilly is in discussions to acquire Ventyx Biosciences for more than $1 billion, according to a report by
- ago 5 days
- •
- 6 Min Read
Eli Lilly is in discussions to acquire Ventyx Biosciences for more than $1 billion, according to a report by